2-bromo-3',4,4',5'-tetrahydroxydiphenylmethane | 1130428-28-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-3',4,4',5'-tetrahydroxydiphenylmethane
• 英文别名: 4-Bromo-5-[(3,4-dihydroxyphenyl)methyl]benzene-1,2-diol
• CAS: 1130428-28-2
• 化学式: C₁₃H₁₁BrO₄
• 分子量: 311.132
• InChiKey: KMDCNITUEFJJNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  双(3,4-二甲氧基苯基)甲酮 在 三乙基硅烷 、 溴 、 三溴化硼 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-bromo-3',4,4',5'-tetrahydroxydiphenylmethane
  参考文献：
  名称：

  溴酚作为具有抗糖尿病特性的蛋白酪氨酸磷酸酶1B的抑制剂

  摘要：

  合成了一系列溴酚衍生物，并基于溴酚4e（IC 50  = 2.42μmol / L）进行了体外和体内蛋白质酪氨酸磷酸酶1B（PTP1B）抑制剂的评价，该化合物是从红藻Rhodomela confervoides中分离得到的。结果表明，所有合成的化合物在测试浓度下均表现出从弱到良好的PTP1B抑制作用。其中，高度溴化的化合物4g对PTP1B表现出有希望的抑制活性，IC 50为0.68μmol/ L，比铅化合物4e的效力高约四倍。此外，化合物4g对其他PTP（TCPTP，LAR，SHP-1和SHP-2）具有很高的选择性。更重要的是，化合物4g的体内抗糖尿病活性研究也显示了令人鼓舞的结果。

  DOI：

  10.1016/j.bmcl.2012.02.074

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：PROTEOTECH INC

  公开号：WO2012118935A1

  公开（公告）日：2012-09-07

  Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

  用于治疗α-突触核复合物病和tau蛋白病的化合物及其药用盐。
• Compounds for the treatment of neurodegenerative diseases
  申请人：ProteoTech Inc.

  公开号：US20150011604A1

  公开（公告）日：2015-01-08

  Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

  化合物及其药用可接受的盐，用于治疗突触核蛋白病，例如帕金森病和tau蛋白病。
• Compounds for the treatment of Neurodegenerative Diseases
  申请人：PROTEOTECH INC

  公开号：US20150274681A1

  公开（公告）日：2015-10-01

  Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

  化合物及其药学上可接受的盐，用于治疗tau病变，例如阿尔茨海默病、皮克氏病、进行性上核性麻痹、皮质基底节变性、17号染色体关联的家族性额颞叶痴呆/帕金森综合征、肌萎缩侧索硬化/帕金森综合征-痴呆复合症、银染颗粒性痴呆、拳击性痴呆、伴有钙化的弥漫性神经纤维缠结、进行性皮层下胶质增生和仅有缠结的痴呆。
• Synthesis and antimicrobial activities of halogenated bis(hydroxyphenyl)methanes
  作者：Ki-Bong Oh、Ji Hye Lee、Jong Wook Lee、Kyung-Mi Yoon、Soon-Chun Chung、Heung Bae Jeon、Jongheon Shin、Hyi-Seung Lee

  DOI：10.1016/j.bmcl.2008.11.089

  日期：2009.2

  A series of halophenols was prepared by the reaction of bis(hydroxyphenyl) methanes with effective halogenating agents such as bromine and sulfuryl chloride. One of these compounds, a biologically active halophenol-2,2',3,3'-tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane (1)-frequently isolated from red algae, was synthesized for the first time. Other halophenols included several novel compounds, together with known derivatives that were synthesized from the phenolic intermediates, bis(3,4-dihydroxyphenyl) methane (5) and bis(2-hydroxyphenyl) methane (14). All of the synthesized compounds were tested for antimicrobial activity against Gram-positive, Gram-negative bacteria and fungi. The preliminary structure-activity relationship was investigated in order to determine the essential structural requirements for their antimicrobial activity. Of all these halophenols, 2,2',3,3',6-pentabromo-4,4',5,5'-tetrahydroxydiphenylmethane (8) was found to be the most active against Candida albicans, Aspergillus fumigatus, Trichophyton rubrum, and Trichophyton mentagrophytes while 3,3',5,5'-tetrachloro-2,2'-dihydroxydiphenylmethane (18) exerted a powerful antibacterial effect against Staphylococcus aureus, Bacillus subtilis, Micrococcus luteus, Proteus vulgaris, and Salmonella typhimurium. (C) 2008 Elsevier Ltd. All rights reserved.
• COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：PROTAMED, INC.

  公开号：US20170022174A1

  公开（公告）日：2017-01-26

  Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.